TZIELD™ (teplizumab-mzwv) is a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and pediatric patients aged 8 years and older with Stage 2 T1D. This medication modifies T cell function to preserve beta cell function and is administered as a daily intravenous infusion for 14 consecutive days.
Medical Director
Director of Partnerships
Simplify patient referrals and offer advanced treatment options with our infusion partnership program.
There may be a better way to manage your condition – explore infusion therapy.